Settling in

Kibbe, Cindy
December 2010
New Hampshire Business Review;12/3/2010, Vol. 32 Issue 25, p4
The article reports that approximately 1.3 million dollars of national settlements was received by New Hampshire from two pharmaceutical companies.


Related Articles

  • Gifting Laws Cause Regulatory Woes. Buzzeo, Ron // Pharmaceutical Executive;Jun2006, Vol. 26 Issue 6, p114 

    The article reports on the burden of a legislation that increases monetary penalties against drug companies in the pharmaceutical industry in the U.S. The legislation does not one come from the federal government, but also from individual states, which implies bigger headaches, more monetary...

  • Bayer Pays $14MM Fine In Drug Pricing Issue.  // Chemical Market Reporter;09/25/2000, Vol. 258 Issue 13, p7 

    Reports on the fine which Bayer Corporation has agreed to pay to settle the federal investigation of its pricing practices in the United States. Statement issued by the company; Other pharmaceutical companies under investigation on pricing practices.

  • STRATEGIC INSIGHTS Regulatory Compliance. Strattner, Tony // Bio-IT World;Jan2004, Vol. 3 Issue 1, p44 

    Presents information on challenges facing drug companies in the U.S. as of January 2004. Allegations of drug-pricing fraud; Fine imposed by the U.S. government on drug companies due to such allegations.

  • Cambrex Faces Fine for 2007 Fire in Iowa. Scott, Alex // Chemical Week;3/10/2008, Vol. 170 Issue 8, p27 

    The article reports on the $15,000 in fines that will be faced by Cambrex if it will be found guilty of health and safety violations related to an explosion in 2007 at its Charles City, Iowa complex. The citation is related to an October 2007 fire and explosion in Cambrex's pharmaceutical drying...

  • NPPA gets Rs. 672-cr from pharma companies as fine for overcharging.  // FRPT- Chemical Snapshot;4/4/2017, p18 

    The article offers information on several pharmaceutical companies has been charged with fines by National Pharmaceutical Pricing Authority, drug pricing regulator for overcharging on sales of formulations at prices above notified ceiling price.

  • What a Piece of Work Is Pharma. Hoffman, Michelle // Pharmaceutical Technology;Jan2011, Vol. 35 Issue 1, p12 

    The article focuses on the report "Rapid Increasing Criminal and Civil Monetary Penalties Against the Pharmaceutical Industry: 1991 to 2010. The report suggests that a nontrivial aspect of that increase came from corporate misconduct. Furthermore, it states that only 3% of all 184 violations...

  • Feds issue guide on average sales price.  // Drug Topics;4/19/2004, Vol. 148 Issue 8, p8 

    Reports on the interim final rule requiring manufacturers to submit their average sales price (ASP) data for certain Medicare Part B drugs and biologicals issued in the U.S. Discounts that must be included in the ASP calculation; Penalties that may be levied for each price misrepresentation.

  • An unhealthy disregard.  // Nature Medicine;Jun2010, Vol. 16 Issue 6, p609 

    The author reflects on the illegal promotion of drugs by pharmaceutical firms. The author mentions that for the promotion of their products and improvement of sales the companies pay heavy fines to the government but carry on with the illegal promotion of drugs. The author further mentions that...

  • US drug companies have paid $15bn in fines for fraudulent marketing. Tanne, Janice Hopkins // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/1/2011, Vol. 342 Issue 7787, p11 

    The article reports that illegal marketing activities of drug companies in the U.S. have increased, resulting in large penalties for prosecuted companies.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics